4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection.
This study demonstrates that PCV13 is immunogenic and safe in children previously vaccinated with PCV7. By eliciting high antibacterial immune responses to the additional serotypes, PCV13 provides protection against these serotypes, which are important causes of pneumococcal disease globally.
The evidence presented in the article strongly supports the notion that serotype replacement has occurred in invasive pneumococcal disease in most populations and is caused by the vaccine.
Between 21 May and 5 December, 2011, 63 cases of Plasmodium vivax infection have been reported in Greece. The majority of cases (n=57) are reported from the area of Evrotas in Lakonia district, Peloponnese in southern Greece.
Since the 21 June, ECDC has published on its website weekly updates on spatial distribution of West Nile fever cases in the European Union and neighbouring countries.
Universal screening of pregnant women is feasible and has led to immunisation in nearly all identified cases in Denmark. As a consequence of the study the National Board of Health has made universal HBsAg screening of pregnant women permanent in the country.
ECDC publishes weekly West Nile fever maps, based on information provided by the health authorities across Europe, with the objective to inform the national competent authorities about WNV affected areas.
According to the available epidemiological and entomological information, and the arriving winter season, the intensity of malaria transmission in Evrotas, Lakonia in Greece is very low.